Company news
Vaxcyte, Inc. news in 2022
Vaxcyte, Inc.'s news releases, calls and decks from 2022, newest first.
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
December 19, 2022
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
November 6, 2022
Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 27, 2022
Vaxcyte Announces Pricing of $600 Million Public Offering
October 25, 2022
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
October 23, 2022
Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
October 22, 2022
Vaxcyte Expands Executive Leadership Team with Key Appointments
October 10, 2022
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older
September 5, 2022
Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update
August 7, 2022
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
August 3, 2022
Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults
July 11, 2022
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
June 26, 2022
Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
May 8, 2022
Vaxcyte to Participate in Upcoming Investor Conferences in May
May 2, 2022
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
April 4, 2022
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
April 3, 2022
Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 27, 2022
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
February 22, 2022
Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
February 16, 2022
Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 9, 2022
Vaxcyte Announces Pricing of $100 Million Public Offering
January 12, 2022
Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 11, 2022
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
January 5, 2022
Calls in 2022
Decks in 2022
- Technical Presentation (October 2022)
Technical · 35 slides · Oct 24, 2022